Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 8 January 2026 - 9 January 2026

China SXT Pharmaceuticals (SXTC) stock whipsaws after AI “clinics” plan, with Friday open in focus

China SXT Pharmaceuticals (SXTC) stock whipsaws after AI “clinics” plan, with Friday open in focus

New York, Jan 9, 2026, 06:19 EST — Premarket China SXT Pharmaceuticals Inc shares ended Thursday down 37.5% at $1.25 after swinging between $1.21 and $6.98, with volume jumping to about 109.3 million shares, Yahoo Finance data showed. The day before, the stock closed at $2.00 on roughly 115,000 shares. (Yahoo Finance) The China-based maker of traditional Chinese medicine products said it launched a “Strategic Artificial Intelligence (AI) Insights Initiative” to apply AI analytics to product planning, market intelligence and research decisions, and it plans offline AI-supported consultation stores across China. “Leveraging AI to gain insight into product trends and
9 January 2026
··
GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom

GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom

London, Jan 9, 2026, 10:50 GMT — Regular session GSK (GSK.L) shares were down 0.6% at 1,879.5 pence by 1050 GMT, trading in a 1,871p to 1,886p range. (London South East) The stock is still digesting a phase III win for bepirovirsen, GSK’s experimental chronic hepatitis B treatment, which the company says achieved a “functional cure” — meaning the virus can no longer be detected in blood tests for a sustained period after treatment. GSK said it plans to start global regulatory filings from the first quarter of 2026 and described bepirovirsen as an antisense oligonucleotide, a short strand of
9 January 2026
···
AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls

AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls

New York, Jan 8, 2026, 19:33 EST — After-hours AbbVie shares dropped 4% on Thursday, slipping to $224.13 in after-hours trading from a previous close of $233.41, as investors digested a profit forecast reduction linked to a hefty charge. The move matters because AbbVie is scrambling to make up lost ground after Humira’s patent expired, leaning heavily on acquisitions to sustain its growth. Traders have been quick to pounce on any whispers of another big deal, especially after takeover chatter about cancer-drug developer Revolution Medicines briefly lifted AbbVie shares just a day before. Reuters AbbVie revealed in a filing that
9 January 2026
···
MoonLake stock jumps after FDA feedback clears path for sonelokimab filing without new HS trials

MoonLake stock jumps after FDA feedback clears path for sonelokimab filing without new HS trials

New York, Jan 8, 2026, 17:06 EST — After-hours MoonLake Immunotherapeutics shares jumped 27% to $14.34 on Thursday after the biotech said U.S. regulators supported a route to file its hidradenitis suppurativa treatment without doing more trials for the skin disease. The stock churned between $11.20 and $17.28, and roughly 24 million shares traded. The update is a big deal because it clears up a near-term unknown: whether MoonLake would need to pay for and run another late-stage study before it can seek approval. For a clinical-stage company with no product revenue, that sort of timing decision can jolt the
8 January 2026
···
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

New York, Jan 8, 2026, 13:46 EST — Regular session Merck & Co shares rose 1.5% to $110.20 in afternoon trading on Thursday after Wolfe Research upgraded the drugmaker, outpacing a softer health-care sector. The stock traded as high as $112.08 and as low as $107.94, while AbbVie slid about 3.9% and the S&P 500 ETF was little changed. The move comes as investors try to sort out two cross-currents: Merck’s push to broaden its pipeline and a fast-moving U.S. debate over vaccine policy that touches one of its biggest franchises. Merck said it will report fourth-quarter and full-year 2025
8 January 2026
····
Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

New York, Jan 8, 2026, 10:13 EST — Regular session Pfizer Inc shares rose 0.3% to $25.36 on Thursday after a U.S. appeals court blocked a Trump administration pilot that would have changed how safety-net hospitals pay for some medicines. The program covered the first 10 drugs heading into Medicare price negotiations, including Pfizer and Bristol Myers Squibb’s blood thinner Eliquis, and the American Hospital Association said it would have a “devastating effect.” Reuters Why it matters now is less about a single day’s trade and more about the plumbing of drug pricing. The 340B program requires manufacturers to sell
8 January 2026
··
Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

NEW YORK, Jan 8, 2026, 08:59 (EST) — Premarket Omeros Corp (OMER.O) shares were up 0.55, or about 4%, at $14.09 in premarket trade on Thursday after the drugmaker set a $36,000 price for each single-dose vial of its newly approved Yartemlea treatment for transplant-associated thrombotic microangiopathy (TA-TMA). “Median utilization was 8 to 10 vials per treatment course,” Chief Executive Gregory Demopulos told analysts. The stock rose 6.6% in extended trade on Wednesday. Reuters The pricing matters because Omeros is trying to turn a long-running development story into a launch, with Yartemlea (narsoplimab-wuug) positioned as the first and only approved
8 January 2026
··
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

New York, January 8, 2026, 05:14 (EST) — Premarket AbbVie Inc (ABBV) shares slipped 1.6% to about $229.64 in premarket trading on Thursday after the drugmaker denied it was in talks to buy cancer biotech Revolution Medicines and cut its 2025 profit view. Revolution’s stock fell 11.5% in extended trading after AbbVie’s statement, Reuters reported. Investing.com+1 The whiplash matters because AbbVie has become a deal story again, and the market is quick to mark it up or down on anything that hints at the next growth lever. The company is due to report full-year and fourth-quarter 2025 results on Feb.
8 January 2026
···
GSK share price slips as hepatitis B drug headline leaves investors wanting the numbers

GSK share price slips as hepatitis B drug headline leaves investors wanting the numbers

London, Jan 8, 2026, 09:12 GMT — Regular session GSK (GSK.L) shares slipped on Thursday as investors weighed upbeat headlines on its experimental hepatitis B therapy against a lack of hard cure-rate data. The stock was down 0.9% at 1,883.5 pence in London trade, after moving between 1,880 and 1,896.5 pence and staying near the top of its 52-week range. Investing.com+1 GSK said two Phase III trials of bepirovirsen met their primary endpoint — the main goal set before the studies began — and delivered a statistically significant “functional cure” rate on top of standard treatment. A functional cure, as
8 January 2026
··
Regeneron stock pops on BofA double-upgrade as 2026 catalysts stack up

Regeneron stock pops on BofA double-upgrade as 2026 catalysts stack up

New York, Jan 7, 2026, 20:51 EST — Market closed Regeneron Pharmaceuticals shares climbed 4.6% on Wednesday after Bank of America upgraded the drugmaker to “Buy” from “Underperform” and raised its price objective to $860. Investing.com The call matters because Regeneron’s stock has been stuck in a tug-of-war: investors want proof the company can defend its eye-medicine franchise as rivals and copycat versions crowd the field, while newer products and pipeline shots sit further out. BofA wrote that earlier worries around the standard-dose version of Eylea have been priced in, and it is now leaning on a faster shift to
8 January 2026
··
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

New York, Jan 7, 2026, 18:52 EST — After-hours Merck & Co (MRK.N) shares edged down in after-hours trading on Wednesday after U.S. health officials updated the childhood immunization schedule and moved to a single dose for the human papillomavirus (HPV) vaccine, a change that could pressure demand for Merck’s Gardasil shot. The stock was down about 0.2% at $108.60, after trading between $107.99 and $111.42 in the regular session. HHS.gov The CDC move lands at an awkward moment for Merck, which relies on Gardasil as its biggest vaccine franchise and a key growth lever alongside cancer drug Keytruda. Jefferies
8 January 2026
····
AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

New York, Jan 7, 2026, 18:35 EST — After-hours AbbVie (ABBV.N) shares were down about 1% at $231.11 in after-hours trading on Wednesday after the drugmaker denied a Wall Street Journal report that it was in advanced talks to buy cancer-drug developer Revolution Medicines (RVMD.O), saying it “is not in discussions with Revolution Medicines.” The stock had closed up 4.2% at $233.42, while Revolution shares slid 11.5% late after jumping nearly 30% earlier, with the report pointing to a valuation around $20 billion. AbbVie has spent more than $20 billion on acquisitions since 2023 as its former blockbuster Humira lost
8 January 2026
····
1 … 20 21 22 23 24 … 56

Stock Market Today

Kenvue stock price holds near $18 as Kimberly-Clark deal math tightens — what to watch next week

Kenvue stock price holds near $18 as Kimberly-Clark deal math tightens — what to watch next week

7 February 2026
Kenvue shares closed Friday at $18.13, up 0.33%, with about 63.5 million shares traded. The Kimberly-Clark offer values Kenvue at roughly $18.76 per share, leaving a deal spread of about 3%. Both companies’ shareholders approved the merger, which is expected to close in the second half of 2026 pending regulatory approvals. Kenvue’s dividend record date is Feb. 11, with earnings due Feb. 17.
IREN stock heads into Monday after 5% rebound as Microsoft AI financing stays in focus

IREN stock heads into Monday after 5% rebound as Microsoft AI financing stays in focus

7 February 2026
IREN shares closed up 5.1% at $41.83 Friday after reporting a $155.4 million quarterly loss and $184.7 million in revenue. The company announced $3.6 billion in GPU financing for its Microsoft contract, with $2.8 billion in cash as of Jan. 31. Bitcoin mining revenue fell, while AI cloud services rose. Traders await bitcoin’s weekend move and Monday’s market reaction.
Cadence Bank stock is stuck at $42.11 after Huntington deal — what CADE holders watch next week

Cadence Bank stock is stuck at $42.11 after Huntington deal — what CADE holders watch next week

7 February 2026
Cadence Bank shares have been delisted following Huntington Bancshares’ takeover, with each Cadence share converted into 2.475 Huntington shares. Huntington closed Friday at $19.27 and named Senthil Kumar as chief risk officer ahead of new regulatory requirements. The merger leaves Cadence as a brand under Huntington, with customer account conversions planned for mid-2026. Huntington executives will address investors at a UBS conference on Tuesday.
Go toTop